Table 2 Detailed clinical parameters of enrolled SSc patients
Sample ID | Sex (F/M) | Disease duration (years) | Auto-antibody profile | NVC pattern (E/A/L) | Skin involvement (lcSSc/dcSSc) | ILD (Yes/No) | GI involvement (Yes/No) | PAH (Yes/No) | Renal involvement (Yes/No) | DUs (Yes/No) | FVC | DLCO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SSc1 | F | 23 | Scl70 | L | dcSSc | Yes | Yes | Yes | Yes | Yes | 77 | 44 |
SSc2 | F | 23 | Scl70 | L | lcSSc | Yes | Yes | Yes | No | Yes | / | / |
SSc3 | F | 16 | Scl70 | A | lcSSc | Yes | Yes | Yes | No | Yes | 88 | 93 |
SSc4 | F | 14 | Scl70 | A | lcSSc | Yes | No | No | Yes | No | 97 | 53 |
SSc5 | F | 4 | Scl70 | L | dcSSc | Yes | No | No | No | Yes | 108 | 70 |
SSc6 | F | 11 | CENP-A/B | A | lcSSc | No | No | No | Yes | No | 85 | 85 |
SSc7 | F | 3 | CENP-A/B | A | lcSSc | No | No | No | Yes | No | 110 | 97 |
SSc8 | F | 15 | CENP-A/B | A | lcSSc | No | Yes | No | Yes | No | 119 | 75 |
SSc9 | M | 13 | Scl70 | E | lcSSc | Yes | No | No | Yes | No | 93 | 90 |
SSc10 | F | 2 | CENP-A/B | A | lcSSc | Yes | Yes | No | Yes | No | 113 | 91 |
SSc11 | F | 16 | Scl70 | L | dcSSc | Yes | Yes | No | No | Yes | 26 | 27 |
SSc12 | M | 6 | Scl70 | A | lcSSc | Yes | Yes | No | No | Yes | 74 | 92 |
SSc13 | F | 1 | Scl70 | L | lcSSc | Yes | Yes | No | No | Yes | 68 | 47 |
SSc14 | F | 4 | CENP-A/B | L | dcSSc | No | Yes | No | No | Yes | 52 | / |
SSc15 | F | 4 | CENP-A/B | A | lcSSc | No | No | No | No | No | 119 | 142 |
SSc16 | F | 4 | CENP-A/B | E | lcSSc | No | No | No | No | Yes | 103 | 93 |
SSc17 | F | 7 | CENP-A/B | A | lcSSc | No | Yes | No | Yes | No | 93 | 102 |
SSc18 | F | 9 | Scl70 | A | lcSSc | Yes | Yes | Yes | Yes | Yes | 86 | 47 |